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ABSTRACT

SHAUNTA S. PARKER
A Geographic Information System (GIS) Analysis of Cancer Clinical Trial Locations in
the State of Georgia by Major Cancer Type
(Under the direction of Dr. Michael Eriksen, Faculty Member)
Improving cancer care through clinical research is a major public health issue. However,
in Georgia, the exact number of cancer clinical trials is unknown, indicating the need for
baseline data regarding cancer clinical trial locations and cancer burden. This study
provides the first statewide analysis of cancer clinical trial locations using Geographic
Information Systems (GIS). This study examines cancer clinical trial locations by county,
according to incidence rates, racial patterns and mortality rates of the four major cancer
types: breast, colorectal, lung, and prostate. Findings from this study suggest that metroAtlanta counties have higher densities of cancer clinical trials. This study also found that
there were little or no cancer clinical trials available in counties with the highest rates of
overall incidence, African American incidence and overall mortality. This research
demonstrates the need to increase availability of cancer clinical trials in counties with the
highest cancer burden.

INDEX WORDS: Cancer clinical trials, Geographic Information Systems (GIS), cancer
burden, racial disparities, availability of cancer clinical trials
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Chapter I – Introduction
Cancer is the second leading cause of death in the state of Georgia.
Approximately 13,500 Georgians die from cancer each year and an estimated 36,000
Georgia residents are diagnosed annually. The most common forms of cancer in the state
include breast, prostate, colorectal, lung cancer, accounting for 58 percent of all cancer
diagnosed and 53 percent of all cancer deaths. Cancer is a serious public health issue that
can be addressed in a variety of ways including prevention and treatment, particularly in
cancer clinical trials (Singh et al. 2005). Cancer is commonly treated by surgery,
radiation, chemotherapy, hormones, immunotherapy or a combination of two or more of
these methods. Due to the severity of this disease, prevention and treatment of this
disease have become increasingly important. Cancer treatment has improved over time
due to advancements in clinical research (Ford et al. 2005).
Clinical trials provide an important tool that assists in the advancement of
research and cancer treatment, thereby reducing cancer mortality and in some cases
morbidity (through prevention trials). Clinical trials are also vital in the determination of
effective therapies for cancer treatment and prevention. For many patients, clinical trials
provide an opportunity to receive cutting edge treatment (Comis et al. 2003).
Yet, enrollment for cancer clinical trials across the state remains low (Murthy et
al. 2004). Researchers have conducted studies revealing reasons that cancer patients do
not participate in clinical trials. Recent studies suggest that only 3 percent of cancer
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patients participate in clinical trials (Sateren et al. 2002). This is scant compared to the
fact that over 60 percent of children with cancer participate in cancer clinical trials. This
issue has spurred numerous studies geared to identify barriers associated with cancer
clinical trial enrollment. Numerous barriers to cancer clinical trial enrollment have been
found, some of which include geography, racial obstacles and physician awareness (NCI
2001). Racial obstacles regarding cancer clinical trial enrollment is a major public health
issue due to the disproportionate burden of the disease. In Georgia, African American
males are 20 percent more likely to be diagnosed with and 39 percent more likely to die
from cancer than their white counterparts. In addition, breast cancer mortality rates for
African American women in the state are 33 percent higher that Caucasian women.
African American women in Georgia also experience colorectal cancer mortality rates 71
percent higher than their white counterparts (Singh et al. 2005). Yet, African Americans
have lower cancer clinical trial participation than whites (Corbie-Smith et al. 2004). It is
important to ensure that clinical trial participants reflect the entire population and that
cancer clinical trial results are generalizable (Etling et al. 2006).
This issue gives rise to concerns of whether there is sufficient availability of
cancer clinical trials for those most affected by the disease. Because there is no
centralized cancer clinical trial database and the various cancer clinical trial registries are
not linked, obtaining information regarding sufficient availability within the state can be
daunting (McCray 2000). There is a national registry for clinical trials
(www.clinicaltrials.gov), but it hosts trials for all diseases and may not always include
local level details regarding specific locations for oncology practices. There is also a
national database for cancer clinical trials, TrialCheck™ (www.trialcheck.org) which
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supports the Georgia Cancer Trials database. This makes Georgia unique, as one of the
few states in the U.S. with a state-specific cancer clinical trial database. Before the
Georgia Cancer Trials database, monitoring and assessing the quantity and distribution of
trials in the state was virtually nonexistent. This left Georgia grappling with many other
states regarding the issue of whether there is sufficient availability of cancer trials for
affected populations.

Purpose of this study
Utilizing data gathered from Georgia’s only statewide cancer clinical trial
registry, Georgia Cancer Trials, this paper will reveal the geographic distribution of
cancer clinical trials in the state and also expose racial disparity patterns in those areas.
This thesis will use Geographic Information Systems (GIS) as an analysis tool to
graphically display cancer clinical trial locations throughout the state. In an effort to
address issues of information asymmetry, this thesis will provide baseline data regarding
the geographic distribution of cancer clinical trials in the state, by cancer type, in a format
that is consistent with the current cancer incidence reporting mechanism, GIS. This
research will also show the racial patterns in those areas to provide information or details
regarding the racial disparities in specific locations. The data will be presented at the
county level.
Viewing the geographic distribution of cancer clinical trials in Georgia through
GIS mapping systems will create data that may assist with the state cancer plan and with
potential strategic placement of needed cancer centers and cancer clinical trials across the
state. It is hypothesized that many of the cancer clinical trials are located in the heavily
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populated metro-Atlanta area, as opposed to rural areas where cancer clinical trial
opportunities may be scant. Many times, rural areas of Georgia exhibit a higher cancer
incidence rate than the metro-Atlanta areas. Obtaining data to confirm or refute this
assumption is necessary in developing a strategic approach to advancing cancer clinical
research in the state and determining if there are vast disparities in cancer clinical trial
availability in specific areas.

Study Objectives
1) To identify the geographic distribution of cancer clinical trials in Georgia by
cancer type.
2) To examine the racial patterns of cancer incidence rates surrounding cancer
clinical trial geographic locations.
3) To establish baseline data for cancer clinical trial locations across the state.
4) To make recommendations regarding strategic cancer clinical research
improvement.

Research Questions
1) What is the geographic distribution of cancer clinical trials in Georgia?
2) Are trials available in counties experiencing the highest burden of the disease?
3) Is there a disparity in cancer clinical trial locations as it relates to racial pattern?
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This paper will provide an analysis of cancer clinical trials in Georgia by major
cancer type using GIS. The review literature will highlight issues related to cancer
clinical trial participation and how GIS can be used in cancer clinical research. Chapter
III will detail the methods and procedures used to analyze cancer clinical trials in the
Georgia through the GIS ArcMap application based on the Georgia Cancer Trials
database, cancer morbidity and mortality data. Chapter IV will reveal results found in this
study, providing tables and maps to display where cancer burden is greatest versus where
cancer clinical trials are located in the state. The final chapter will discuss details found in
this study, answer the previously outlined research questions and make recommendations
based on study results.
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Chapter II- Review of Literature
Cancer is a major cause of death in Georgia, accounting for 21 percent of all deaths in
the state. In Georgia, prostate, breast, lung, and colorectal cancer are among the most
common cancer types, accounting for 53 percent of all cancer deaths in the state (Singh et
al. 2005), as seen in Figure 2.1.

Figure 2.1 Leading Causes of Death, Georgia, 1998-2002

*Source: Georgia Cancer Data Report, 2005

There is great concern in the cancer research community regarding the low
enrollment of cancer patients in cancer clinical trials. The need for more patients to enroll
in trials has spurred the conduction of research to review why patients participate in
cancer clinical trials. Many oncologists are concerned about whether there a sufficient
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trials available. According to the Georgia Department of Human Resources, Division of
Public Health, an estimated 39,520 Georgians were diagnosed with invasive cancer in
2006. Recent studies suggest that burden of disease is higher in rural areas of Georgia,
compared to metro areas. According U.S. statistics, males have a 1 in 2 lifetime risk of
developing cancer while women have a 1 in 3 lifetime risk. The severity of this disease
gives implications for the importance of cancer clinical trials and developing a cure for
the disease (Singh et al. 2005).
This review of literature will discuss cancer clinical trial basics and registry issues. In
addition, the following topics related to cancer clinical trial participation will also be
reviewed: racial/ethnic issues, socioeconomic status and cancer trials, effects of distance
and cancer trial locations. It is important to review these topics not only because they are
directly related to the research conducted in this paper, but also because they encompass
the various reasons why patients enroll in cancer clinical trials.

Cancer Clinical Trials Background
Clinical trials represent how advancements in research are made and answer
important questions regarding whether a cancer drug is safe and effective. This section
will describe the various phases of cancer trials, types of cancer trials, and levels of
prevention in cancer trials.
There are 4 phases to cancer clinical trials. Phase I cancer trials evaluate how new
drugs should be given, how often they are given, and what dose is safe in humans. Phase
II cancer trials test the safety of the new drug, and begin to evaluate how well the new
drug works on a particular cancer type. Phase III cancer trials test a new drug, a
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combination of drugs, or a new surgical procedure in comparison with the current
standard of treatment. Phase IV cancer trials review the long term safety and benefits of a
treatment. This phase continues after the study treatment has been approved for use and
doctors are able to give it to patients routinely. These trials can be used to gather
information on any side effects that may have been missed in the earlier trials (NCI
2001). Figure 2.2 below exhibits how cancer clinical research translates into patient care.

Figure 2.2 How Cancer Research Moves into Patient Care

* Source: Coalition of Cancer Cooperative Groups, 2006

In addition, cancer clinical trials can also be categorized by type of trial, including
prevention, treatment, supportive care and other. Prevention studies reveal ways of
reducing the risk of getting cancer in one of two ways: by doing something, such as
exercise or quitting smoking (Action studies), or by taking something, such as certain
medicines, vitamins or minerals (Agent studies). Treatment studies test new treatments
such as the following: new cancer drug, new approaches to surgery or radiation therapy,
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new combinations of treatments, or new methods such as gene therapy. Supportive care
studies work to find better methods for caring for the side effects caused by cancer
treatment and the side effects of the cancer itself. Many supportive care studies use drugs
to treat the side effects. Supportive care is given to improve the quality of life for patients
with serious diseases (NCI 2001).
There are three levels of prevention in cancer clinical trials: primary, secondary, and
tertiary prevention. Primary prevention trials are designed to intervene among people
with cancer risk profiles; the objective is to eliminate exposure that could trigger
mutagenesis or carcinogenesis (i.e., in occupational settings). Secondary prevention trials
identify genetic markers, biomarkers, or early diagnosis and clinical manifestation (i.e.,
breast lump, skin lesion, or persistent cough) to stop the process through drugs prior to
serious disease manifestations. Tertiary prevention involves surgical ad adjuvant
chemotherapies or natural remedies to rehabilitation to ensure maximal quality of both
function and life (NCI 2001).

Cancer Clinical Trial Registries
Because the Georgia Cancer Trials registry is a major data source for this paper, it
is important to discuss mandates for cancer clinical trial registries, issues associated with
maintenance of cancer clinical trial registries, and patient utilization of cancer clinical
trial registries.
There are federal mandates requiring the listing of cancer clinical trials in a
database (Hillner 2004). In 1997, a section of the FDA Modernization Act required
creation of a clinical trials database:
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A registry of clinical trials (whether federally or privately funded) of experimental
treatments for serious or life-threatening diseases and conditions….which provides a
description of the purpose of each experimental drug, either with the consent of the
protocol sponsor, or when a trial to test effectiveness begins. Information provided shall
consist of eligibility criteria of participation in the clinical trials, a description of the
location of trial sites, and a point of contact for those wanting to enroll in the trial, and
shall be in a form that can be readily understood by members of the public (McCray
2000).
Cancer clinical trials databases in the US include (but are not limited to) the
following: NCI, NIH registry, National Coalition for Cancer Cooperative Groups,
Oncolink, TrialCheck and Centerwatch (NCI 2001). Though there are federal mandates
for clinical trials registration, trials are registered through various databases and
oftentimes patients are unaware of cancer clinical trial options (McCray 2000). The
Georgia Cancer Trials database is powered by TrialCheck which means that the
nationally registered data is filtered into the state-specific database with more details
regarding actual locations of oncology practices and contact information. Georgia CORE
also adds cancer clinical trials conducted at community practices to the database that may
not be captured at the national level. In addition, the information regarding trials in the
database is sent to the oncology practices for frequent updates, which ensures that the
database is a true representation of oncology clinical research in Georgia. Therefore, the
Georgia Cancer Trials database is a more accurate picture of where cancer clinical trials
are located in the state.
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Dickersin and Rennie (2003) reviewed the importance of clinical trial registration.
They highlighted the need to develop a comprehensive cancer clinical trial registry,
particularly since it is not currently possible to find information regarding all initiated
cancer clinical trials in a central location. This is important because clinical trial registries
are used by physicians and patients to identify which studies are open for enrollment
(Dickersin and Rennie 2003).
Alexa McCrary (2000) conducted a study to investigate associated with cancer
clinical trial registries. McCrary’s study found numerous issues with maintaining clinical
trial registries, some of which included that they required extensive resources to create
and maintain the database; required agreement on standard data elements; required
managing data from multiple sources; required regular updates to ensure accuracy; raised
proprietary concern; and involved technical challenges. He also found that there were
numerous benefits associated with clinical trial registries. For example, they served as
resources for patients, physicians and researchers; helped patients find trials for which
they might be eligible; assisted in accrual of patients; helped physicians identify
treatments under study; and helped in the initiation and design of new trials (McCray
2000).
Wei and colleagues (2004) discussed utilization of an internet-based database to
enroll patients in cancer clinical trials. This study highlighted the increasing use of
internet for patient resources and information regarding cancer clinical trial availability.
Wei and others (2004) reviewed how cancer patients access information regarding
clinical trials by surveying patients who enrolled through internet-based database vs.
telephone call center enrollment. They found that most registrants (88 percent) accessed
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information through the internet. They also found that participants who registered
through the internet were significantly younger than those who registered through the call
center (Wei et al. 2004).
There are many determining factors of cancer clinical trial participation. The
following content will discuss issues associated with patients’ decision to participate in
cancer clinical trials: cancer clinical trial availability, racial/ethnic issues, socioeconomic
status, and effects of proximity to trial locations.

Cancer Clinical Trial Availability
Registries are important in assisting patients with locating cancer clinical trials;
however, an adequate number of trials must be available. Meyer et al. (2006) conducted a
study at the Gundersen Lutheran Cancer Center in Wisconsin to evaluate clinical trial
accrual among patients, as well as the availability of trials for adult cancer patients with
recurrent or progressive cancer treated in the community. They conducted a retrospective
analysis of a specific group of patients who received chemotherapy at the Gundersen
Lutheran Cancer Center from November 2004 to October 2005. They also collected data
regarding the number, sources, and types of cancer clinical trials that were available.
They found that 50 trials were offered, with approximately half of the trials being for the
following cancer types: lung (14 percent), pancreatic (12 percent), renal (10 percent),
head and neck (8 percent), prostate (6 percent), and breast (6 percent). There were no
trials offered in the areas of bladder, colorectal, and gastrointestinal cancers. Of all
participants, only 69 patients (49.3 percent) had trials appropriate for their cancer type
and stage of cancer. Among the patients with available trials, 24 (34.8 percent) were
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eligible to participate. Six of the eligible patients were enrolled in trials, bringing the
overall accrual rate to 4.3 percent (Meyer et al. 2006).
Meyer et al. (2006) identified 140 patients, with an equal number of males and
females and a median age of 66 years at the time of treatment. They concluded that
enrollment was low for cancer patients with recurrent or progressive cancer. More than
80 percent of their cancer patients were denied access to a cancer trial due to protocol
unavailability and ineligibility. As a result, researchers found that cancer cooperative
groups did not provide an adequate number of cancer clinical trials for patients in the
community (Meyer et al. 2006).
Lara and colleagues (2001) conducted a study to evaluate accrual patterns of
cancer clinical trials and to determine potential barriers associated with trial enrollment.
These factors were reviewed because low cancer clinical trial accrual rates may lead to
negative impacts that prolong cancer trial duration, force early closure of key studies and
delay the analysis of essential results. Based on their survey of physicians, they found
that protocol availability was a major factor affecting cancer trial accrual. They also
found that of the 62 percent of patients that physicians considered for clinical trials, 47
percent of them had no available protocols at the time of the survey. Lara and colleagues
(2001) also found that physicians who refrained from informing patients about cancer
clinical trials cited that the perception that there were no available protocols appropriate
for the patient’s specific tumor site and stage was the most common reason for doing so.
This is an important concept that leads back the unequal gradient of information or
information asymmetry. Because physicians perceived that there were no trials available,
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based on their lack of information, many patients were not offered cancer clinical trials as
treatment option (Lara et al. 2001).
A study on barriers to cancer trial accrual was conducted by Baggestrom and
colleagues (2006) and presented at the 2006 American Society of Clinical Oncology
(ASCO) meeting. In this study, Baggestrom et al. (2006) reviewed outpatient charts for
all patients with thoracic malignancies that were referred by the thoracic medical
oncology group from their institution, including non-small cell lung cancer (NSCLC),
esophageal cancer, and small cell lung cancer. They found that the most common reasons
for nonparticipation included protocol ineligibility and geographic issues. Baggestrom
and colleagues (2006) also found that 35 percent of patients were not enrolled in cancer
clinical trials because there was a lack of available appropriate trials during the initial
consultation period. (Baggstrom et al. 2006). It is important to address issues associated
with availability of cancer clinical trials, particularly since a survey conducted by Comis
and colleagues (2003) found that 92 percent of respondents felt that cancer clinical trials
would benefit themselves and others (Comis et al. 2003). It is imperative that appropriate
trials be available to those who desire to participate in research studies.
The number of available cancer clinical trials depends heavily on physician
participation. Somkin and colleagues (2005) identified barriers to physician participation
in cancer clinical trials. Their study found that 63 percent of oncologists agreed that
cancer clinical trials were their treatment choice if available. In addition, nearly 90
percent of the oncologists established that clinical trials provide high quality care.
Somkin et al. (2005) also noted the following barriers to physician involvement in cancer
clinical trials: lack of support staff, lack of information about trials, effort and time for
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informed consent, inadequate money from sponsors, and reduced time for other patients
(Somkin et al. 2005).
It is important to note that at large medical centers like NCI designated cancer
centers, physicians are expected to participate in cancer clinical research in the quest for a
cancer cure and better cancer treatments. Conduction of clinical research by physicians in
community practices is vital in order to increase the availability of cancer clinical trials
(Albrecht et al. 1999). This need was identified by NCI and they developed the
Community Clinical Oncology Program (CCOP) in 1983, in an effort to increase clinical
trial accrual and clinical research involvement. This NCI program allows community
oncologists the opportunity to compete for funding to support their cancer clinical trials
program through a recognized research base, such as the Eastern Cooperative Oncology
Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Leukemia Group B
(CALGB), etc. This program is limited to physicians who are associated with hospitals
that have the capacity to maneuver through the grant process (Cohen 2003).

Racial/Ethnic Issues Associated with Cancer Clinical Trial Participation
Cancer clinical trial participation is low among minority populations. In fact, the
proportion of African American participation has declined over the years (Murthy et al.
2004). Advani and colleagues (2003) conducted a study to understand barriers associated
with cancer trial enrollment in the African American community. This study surveyed
218 cancer patients (72 African American and 146 white patients) from the Duke Cancer
Center and the Duke Oncology Outreach Clinics. They found that more African
American patients than white reported that transportation and cost posed problems with
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access to the clinic. They also noted that the under representation of African Americans
in cancer trials has three major impacts: 1) research findings cannot be generalized to the
entire population when there is questionable applicability to groups of ethnic decent; 2)
certain types of malignancies occur more frequently in various racial/ethnic groups; and
3) many reports have called attention to the power of survival among African American
and Hispanic patients, compared with white patients (Advani et al. 2003).
Baquet and colleagues (2006) investigated predictors of cancer clinical trial
participation in Maryland residents in underserved geographic areas. They found that
among patients recruited to cancer trials, African Americans were significantly less likely
to participate. They also found that childcare and transportation were determining factors
in cancer clinical trial participation, specifically in African American women (Baquet et
al. 2006).
Baquet et al. (2006) also noted several reasons for disparities in clinical trial
participation including the following: availability of trials primarily in academic and noncommunity settings, patient, community, and health professional barrier; historical
factors such as the Tuskegee Syphilis Study and other examples of unethical and
exploitative research; reimbursement issues and concerns and study design issues such as
use of randomization for group assignment, blinding and placebos (Baquet et al. 2006).
These findings were particularly important because in many states, minority and rural
communities suffer distinct disadvantages in accessing quality health care services and
health professionals for cancer prevention, screening, early detection, treatment,
palliative care, and pain management. Generally, African Americans, other minority
populations, rural communities, and uninsured populations have participated in cancer
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clinical trials less than other groups. Due to these disparities in research participation, the
benefits of standardized quality care in clinical trials and advances in the research are not
equally distributed to all communities (Petereit et al. 2005).
Adams-Campbell and colleagues (2004) studied factors associated with enrollment of
African Americans onto cancer clinical trials at Howard University over a two year
period. They found that thirteen cancer treatment trials were approved and opened during
the course of the study. They also found that there was an eligibility rate of 8.5 percent,
with a conditional enrollment rate of 60 percent. Adams-Campbell et al. (2004) also
found that there were no appropriate trials available for 24.2 percent of the patient
population. Co-morbidity of disease caused 17.1 percent of the patients ineligibility for
the studies (Adams-Campbell et al. 2004). This is important because many African
American patients suffer from co-morbidity of diseases that may exclude them from
enrolling in cancer clinical trials.
Brown and colleagues (2000) conducted a study to investigate issues associated with
enrollment of cancer clinical trials among minority women. In this study, they
interviewed newly diagnosed breast cancer patients of the Harper Hospital in Detroit,
Michigan to identify barriers to participation in cancer clinical trials. They also assessed
eligibility of trials and documentation of cancer clinical trial participation. Barriers
identified by African American women included lack of information, fear and perceived
interference with personal responsibilities (Brown et al. 2000).
Fouad and colleagues (2000) held a conference in Tuskegee, Alabama to understand
factors involved in minority recruitment in cancer clinical trials. This meeting engaged a
workgroup of healthcare professional to identify barriers to minority recruitment to
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cancer clinical trials. In this study, physicians in the workgroup noted the following
barriers to minority enrollment in cancer trials: lack of knowledge of available resources,
poor communication between patients and physicians, and lack of appreciation of the
need for clinical trial. Fouad et al. (2000) also found that awareness of the Tuskegee
Syphilis Experiment did not affect cancer clinical trial participation. However, this
finding is not consistent with previous studies that have cited minorities’ distrust of
scientific investigators, government and academic institutions based on the inappropriate
conduct regarding the Tuskegee Syphilis Experiment (Fouad et al. 2000).
There is a substantial need to address issues related to minority participation in cancer
clinical trials. Because decreasing minority cancer clinical trial participation is a major
issue, barriers such as: fear, mistrust, inadequate access to trials, protocol ineligibility,
cultural myths, and transportation costs must be addressed in a calculated manner
(Newman et al. 2006). This is particularly important because more minorities are needed
to participate in cancer clinical trials. This not only helps to increase the generalizability
of cancer clinical trial results (Moinpour et al. 2000), but it also helps determine if there
are genetic or cultural differences which impact cancer outcomes (VanEenwyk et al.
2002).
Low-income populations deal with socioeconomic issues that may prevent them from
participating in cancer clinical trials (Abou-Jawde et al. 2006). The next section will
discuss socioeconomic issues associated with cancer clinical trial participation.
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Socioeconomic Status and Cancer Clinical Trial Participation
Socioeconomic status (SES) also plays a role in cancer clinical trial participation.
Sateren and colleagues (2002) conducted a study to examine the influence of SES on
accrual of patients to NCI-sponsored cancer treatment clinical trials. They assessed how
cancer patients accrued to these trials using a range of socioeconomic, geographic, and
demographic variables as indicators. They also estimated the geographic and
demographic US cancer burden using Census data and NCI Surveillance, Epidemiology,
and End Results (SEER) incidence data, since there is no national cancer reporting
mechanism. By combining census and cancer incidence data, researchers developed a
sketch of the demographic and geographic patterns of cancer in the U.S. Sateren and
colleagues (2002) then calculated the expected number of cancer patients accrued to
trials, by geographic level. They studied the number accrued by age, sex, health insurance
status, geographic location, SES, average income on county level, and county education
level (Sateren et al. 2002).
Sateren et al. (2002) found that the highest percent of adult patients accrued to
trials was between 40 and 55 years of age. The majority of patients enrolled were female
(56 percent). They compared this with SEER data, which indicated that 47 percent of
newly diagnosed patients were female and 53 percent were male. They also found that
there were 119 trials open with women sex-specific cancers and 27 trials open with men
sex-specific cancers. Additionally, the percentage of white patients enrolled in cancer
clinical trials was parallel to the overall population statistics. The percentage of African
American men with cancer and were between 30 and 59 years of age and accrued to a
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clinical trial was lower than the percentage of white men with cancer in the same age
group (Sateren et al. 2002).
Sateren and colleagues (2002) used several measures to determine SES, including
mean county education level, mean county income level, mean county poverty level and
mean state employment rate. Including all measures, areas with higher socioeconomic
levels had significantly higher levels of clinical trial accrual. Also, urban areas with the
largest county incomes had the highest rates of observed clinical trial accrual rates. They
also found that each percentage increase in unemployment was associated with a drop in
observed accrual of almost 37 patients per state, whereas each additional approved cancer
program increased accrual by more than nine patients per state. Also, there were 36.5
fewer patients per 1 percent increase in state unemployment. This study was limited to
enrollees over a 12-month period and data for approximately 24,000 patients. Also,
researchers were limited to data regarding NCI-sponsored cancer clinical trials. In
addition, the study did not include patients accrued from pharmaceutical trials (Sateren et
al. 2002).
SES is an essential predictor of access to cancer care. It is important to understand
how this factor relates to age and race disparities in cancer clinical research. Gross and
colleaugues (2004) conducted a cross-sectional analysis of patients enrolled in NCI
sponsored lung, colorectal, prostate, and breast cancer clinical trials. For each of the four
cancer types, researchers selected 10 cooperative group trials that enrolled the most
patients during the study period. They focused primarily on older women; therefore, trials
with fewer than 5 percent of elderly patients (aged 65 or less) were not included. As a
proxy for SES, researchers used each patient’s zip code to link to the 2000 US Census
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data and derived the proportion of participants living in areas below poverty level. Gross
and colleagues (2004) utilized a stepwise approach to identify discrete recruitment
centers in the Clinical Trial Evaluation Program database. To ensure accuracy, research
assistants used several data sources, including the internet and direct telephone contact
(Gross et al. 2004).
Gross and colleagues (2004) found that low SES was significantly associated with
clinical trial enrollment, even after adjusting for variables such as age, race, and
proximity to the nearby cancer research center. Results from this study also suggest that
African Americans with Medicaid were generally less likely to participate in cancer
research trials than whites. They also found that that white patients were significantly less
likely to reside in areas of high poverty (Gross et al. 2004).
According to Giuliano and colleagues (2000), there are three major reasons why
individuals with lower SES do not participate in cancer clinical trials. First, having lower
SES may result in lower rates of screening and prevention and a higher dependence on
public hospitals where physicians are less likely to be involved in cancer clinical
research. Second, patients with lower SES may have insurance issues, mainly because
they may be more reliant on Medicaid and Medicare insurance. This is unfortunate
because reimbursement with participation in a clinical trial is inconsistent and often
denied by Medicaid and Medicare. Third, concerns with financial survival may take
precedence over health and well-being. Oftentimes, patients with low SES are
discouraged from engaging in cancer prevention and screening activities (Giuliano et al.
2000).

22
Presence or absence of managed care is also an important factor in cancer clinical
trial participation, particularly regarding a physician’s decision to inform patients about
cancer clinical trials (Grunfeld et al. 2002). As indicated by Gross and Krumholz (2005),
managed care plays a substantial role in physicians’ behavior regarding cancer clinical
trial enrollment. Enrolling patients to cancer clinical trials requires a significant
investment of time and money. Clinician-investigators and their staff expend an estimated
150-450 hours enrolling patients to cancer clinical trials, with costs ranging from $1300
to $3900. While resources are scarce and reimbursement structures are static, increasing
demands of clinical trial enrollment are an additional strain. Decreases in clinical
revenues associated with managed care organizations have made many physicians less
reluctant to devote additional resources for cancer clinical trial enrollment (Gross and
Krumholz 2005).
SES is also related to a patient’s ability to travel to oncology practices. Because
travel distance may provide another barrier, it is important to discuss how proximity to
the research facility effects the patient’s decision to enroll in a clinical trial. The next
section will provide a review of this issue.

Effects of Proximity to Trial Locations
It is important to understand how travel distance to cancer facilities effect cancer
clinical trial participation (Athas et al. 2000). Gross and colleagues (2004) analyzed the
effect of travel distance on enrollment of elderly patients to cancer trials. They found that
the geographic location of trial participants was important in 2 ways. Both travel distance
from the trial recruitment center and underlying age distribution of the population were
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related to recruitment of older persons. They also found that participants who lived within
7 miles of a recruitment centers were significantly more likely to be elderly. This is
consistent with other research suggesting that travel time is a frequent reason for
declining to enroll in a clinical trial (Gross et al. 2004).
This is important because enrolling onto a study may often entail undergoing treatment
and clinical assessments in facilities that are further away from the patients’ home than
they would otherwise use (Nattinger et al. 2000). Elderly persons may have more barriers
to travel due to impairments in mobility or cognition (Gross et al. 2004).
A study conducted by Lamont and colleagues (2003) suggests that patients who
travel farther to enroll in a study have better survival (Lamont et al. 2003). Considered
with findings from the Gross et al. study, it is likely that not only are older persons less
likely to travel longer distances to enroll in cancer clinical trials, but those who do may
be a healthier subset of the elderly. Therefore, facilitating travel by addressing logistic
barriers for older persons may improve not only the number of older persons enrolled in
clinical trials but also the generalizability of the results by enabling patients with a broad
spectrum of health status to enroll (Gross et al. 2004).
It is important to have a general understanding of how far patients travel to
participate in cancer clinical trials. Wright and colleagues (2004) conducted a study to
identify the independent predictors of patients’ decisions to enter phase III clinical trials.
A single institution observational cohort study design was employed, using a series of
questionnaires developed to capture trials-related opinions of patients, their physicians,
and clinical research associates. They found that mean reported travel distance to the
cancer center was 38km, ranging from 1- 166km (Wright et al. 2004).
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Gross and Krumholz (2005) conducted an investigation to determine the
relationship between managed care patients and cancer clinical trial enrollment. They
collected data from NCI Cancer Trials Evaluation Program for participation in NCIsponsored cooperative group breast, lung, prostate, and colon cancer trials. Trial
participants were assigned to counties according to zip code of their residence.
Geographic Information System (GIS) data were used to estimate distance, in linear
miles, between the center of each county and the nearest county that had an NCI research
center. County SES was related to trial enrollment. Counties with higher proportions of
their population living below poverty level had substantially lower median enrollment
rates, decreasing from 19.1 in counties with less than 9.1% below poverty to 14.0 in
counties with the highest poverty level. Counties with NCI research centers had a median
rate of 21.7, while counties more than 36.5 miles from the nearest center had a median
rate of 15.5 (Gross and Krumholz 2005).
In Gross and Krumholz’s study, counties with the highest enrollment fraction
were less likely to have 2 or more hospitals with oncology services and tended to be nonurban. In this study, the presence of teaching programs and hospitals was unrelated to
trial enrollment. Urban counties at increasing distance from a research center and with a
higher proportion of the population uninsured or below poverty also tended to have lower
enrollment rates in the multivariate analysis (Gross and Krumholz 2005).
Celaya and colleagues (2006) studied whether proximity to a radiation treatment
facility (RTF) played a role in the treatment choice of women with early-stage breast
cancer. They hypothesized that proximity of the treatment facility to patients’ residence
may play a role in cancer treatment, particularly in rural populations. Their study

25
identified all radiation treatment facilities in the New Hampshire, Maine, Massachusetts,
and Vermont over 4 years. Celaya et al. (2006) geocoded the addresses of each facility
and each patient’s address using Geographic Data Technology (GDT) to an exact street
address or zip code. They also estimated the shortest straight-line distance to a facility
(Celaya et al. 2006).
Celaya and colleagues (2006) found that the average distance between patients’
residence and the nearest RTF was 15.1 miles (ranging from 0.1-89.9 miles; median
13.9). Nearly 25 percent of patients lived greater than 20 miles way from the nearest
RTF. In a multivariate analysis, they also found that women were less likely to have
treatment (breast conserving surgery) with increasing distance from the their residence to
the RTF (Celaya et al. 2006). Issues associated with travel distance are extremely
important in rural areas in which patients may be required to drive farther distances for a
cancer clinical trial.
Paskett and colleagues (2002) conducted a study to investigate cancer clinical trial
enrollment factors in rural patients living in North and South Carolina. In this study,
access to the clinical trial center and transportation as barriers as factors for participation
in cancer clinical trials (Paskett et al. 2002). This study also found that cost and
unfamiliarity of physician were also factors that affected clinical trial participation rates
in rural cancer patients. There are also geographic differences in cancer clinical trial
accrual.
In a study conducted by Sateren and colleagues (2002), geographic differences in
clinical trial accrual were found. Specific states and regions of the US had significantly
lower or higher accrual to clinical trials than the national accrual figures. Northern states
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such as Delaware, Iowa, Minnesota, New Hampshire, and North Dakota had the highest
clinical trial accrual rates per number of cancer incidence cases, whereas southern states
such as Alabama, Arkansas, Florida, West Virginia, Kentucky and Georgia had the
lowest accrual rates per number of cancer incidence. Generally, researchers observed
higher clinical trial accrual rates in suburban areas (Sateren et al. 2002).

Geographic Information Systems (GIS)
GIS combines computer hardware, software, databases, and personnel to manage,
display, map, and analyze information related to spatial phenomena. The term
“geographic information systems” was first used in the 1960s to refer to a computer
system for asking questions of maps showing current and potential land use in Canada
(Richards et al. 1999). GIS technology provides public health researchers and officials
with numerous new types of data. GIS can be used to analyze geographic patterns of
disease. The software displays spatial and temporal patterns of health outcomes (Cromley
2003). GIS information must be compatible with the other software used for analysis;
therefore, geocoding is performed to create geographic points from data that may not
have otherwise been analyzed by this software (Rushton 2003).
Geocoding is a calculation of spatial locations from street addresses. Geocoding
in ArcView GIS is a process that creates a layer of visual information based on locational
data in tabular form and a reference feature theme. Compared with tools and charts, maps
developed using GIS technology can be an extremely effective tool to assist stakeholders
and decision makers in visualizing and comprehending public health problems. However,
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the use of GIS for community health planning and various public health applications
remain a relatively underdeveloped marketplace niche (Rushton et al. 2006).
Basic uses for GIS mapping when visualizing cancer data have been studied by
C.A. Brewer (2006). This study identified various mapping methods and discussed how
each method helps researchers visualize cancer data. Mapping methods included:
chloropleth mapping, color symbols, classing, and proportional symbols (Brewer 2006).
GIS can be used to examine inference. According to Geoffrey Jacquez (2004), strong
inference begins with a set of hypothesis regarding observed phenomena. Researchers
then design a series of critical experiments to systematically test each hypothesis. Spatial
systems typically are large and the spatial phenomena of interest in public health (i.e.,
cancer mortality rates, risky behaviors, demographic changes, and experimental
exposures) are difficult to observe directly and/or change slowly through time. This
makes it difficult, if not impossible, to conduct designed experiments and in any event
there are substantial ethical consideration with experimentation on human population
(Jacquez 2004).
Spatial health researchers must often work with encountered data that have been
collected for some purposes other that her specific study. In many instances, the data are
sampled in a systematic way from a spatially distributed population. However in some
instances spatial analysis plays a critical role in identifying spatial and temporal
relationship in population level data, giving rise to hypothesis that can be evaluated on
additional data to be collected from the same system or on data from analogous spatial
systems (Jacquez 2004).

28
The spatial analyst toolbox includes techniques for quantifying spatial patterns,
modeling risk surfaces, and assessing relationships between cancer outcomes and
potential exposures. These techniques allows researchers to determine whether observed
spatial patterns are statistically significant, to identify the locations of clusters, hot spots
and cool spots, to construct maps, showing excess and deficits relative to a risk model,
and to quantify association between 2 spatial variables (Jacquez 2004).
Recently, GIS has been used to show spatial patterns of cancer morbidity and
mortality trends (Boscoe et al. 2004). This is important for this paper because this GIS
analysis of cancer clinical trials in Georgia joins various data sets to determine if cancer
clinical trials are offered in areas with the highest rates of cancer incidence and mortality.
Spatial patterns will display the relationship between where clinical trials are located and
where disease burden is greatest.

Theoretical Approach in this Study
Disparities in cancer treatment are apparent and researchers agree that it should be
addressed in a strategic manner. However, there is uncertainty regarding the state of
cancer clinical trials and whether there is sufficient availability of cancer clinical trials in
needed areas. This has led many to question whether clinical trials are available for
vulnerable populations. The literature suggests that this type of analysis has not been
graphed on a statewide basis; however, there are few studies conducted at research
centers that address the problem for their particular cancer center. This may lead to
information asymmetry.
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Information asymmetry is a theory that is commonly used in economics to explain
market failure (Smith 2005). For the purposes of this paper, information asymmetry is
defined as the disproportionate gradient between those with knowledge regarding cancer
clinical trials in the state and those who lack the information. In this case, Georgia CORE
would be the information holders and physicians, public health officials, patients, and
advocates that aren’t equipped with the data are at the opposing end of the gradient.
Generally, GIS has been particularly useful in examining cancer incidence and
mortality rates in the U.S. Furthermore, these methods can be used to investigate a
number of geospatially-related questions. While there is no survey associated with this
thesis study, research results from this study will provide baseline details that address
barriers found through previous studies: geographic locations and racial patterns.

What is unknown
There is currently no statewide analysis of cancer clinical trials for Georgia. In
addition, there is no report with baseline data regarding the number of cancer clinical
trials offered in the state by cancer type and cancer clinical trial location. Consequently,
there is no consensus on whether an adequate number of clinical trials are being offered
throughout the state, particularly for underserved populations. Therefore, this thesis will
identify baseline data regarding cancer clinical trial locations across the state by major
cancer type (i.e., breast, colorectal, prostate, and lung). This paper will also explore racial
patterns surrounding areas with cancer clinical trials as an indicator for appropriate access
to trials in the state. GIS will be utilize to address this information asymmetry and
provide a more precise measure for assessing this problem in a manner that is consistent
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with current cancer morbidity reporting mechanisms. The next section will describe the
methods and procedures used to identify, collect, and analyze data in this study.
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Chapter III- Methods and Procedures
Availability and access to cancer clinical trials are important in securing the
quality of cancer care, access to promising therapies and enrollment of cancer patients to
trials. Because cancer clinical trials rely heavily on volunteer participation, it is crucial
that there are appropriate numbers of trials available to needed populations. An adequate
number of trials must be present in order for patients who qualify for the study to enroll.
The exact number of cancer clinical trials is currently unknown across the state. Many
oncologists and health officials are left to guess regarding the number of cancer clinical
trials are in Georgia and their locations. The state-specific, Georgia Cancer Trials
database provides a link to the information asymmetry occurring regarding the clinical
trial availability. The database is provided through the Georgia Center for Oncology
Research and Education, Inc. (Georgia CORE). It is made available through a partnership
between Georgia CORE and the Coalition of Cancer Cooperative Groups.
This study was granted exempt-review from the Georgia State University
Institutional Review Board, protocol number H07279: approval letter number 17718. Dr.
Michael Eriksen was listed as the Principal Investigator and Shaunta Parker as the
Student Principal Investigator.
This study was conducted to understand where cancer clinical trials are located by
major cancer type and determine if cancer clinical trials in Georgia were offered in
counties with highest disease burden, using GIS. Also, geographic racial patterns
regarding cancer incidence rates were taken into account in order to determine if
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adequate trials were offered in disparate populations where the disease burden may be
greater. Generally, GIS analysis takes a stepwise approach, from defining the problem to
examining and displaying the results, as seen in Figure 3.1.

Figure 3.1 GIS Analysis Process Map

*Source: ESRI, 2007

The process map displayed in figure 3.1 outlines the method of analysis used in
this study. In this study, the problem is defined as the lack of information regarding
where cancer clinical trials are located in Georgia and whether trials are offered in
counties most affected by the disease.
The next step, using the GIS process map as a guide, defined the criteria for this
study. The following factors were included in this study: open active adult cancer clinical
trials and their corresponding oncology practices in Georgia. The study did not include
childhood cancer clinical trials. The dependent variable of this study includes the quantity
of cancer clinical trials. Factors evaluated in this study include counties with trials, cancer
incidence and mortality rates by major cancer type and African American cancer
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incidence rates. The design of this study called for the listing of all cancer clinical trials
along with their corresponding addresses for mapping purposes. In order to view trial
locations in the ArcView GIS application, each cancer clinical trial listing required
geocoding.
The next step, based on the process map in figure 3.1, identified the data required
for this study. Cancer clinical trial location information was collected from the Georgia
Cancer Trials database; GIS county shapefile data was collected from the Office of
Health Information and Policy’s website; and cancer morbidity and mortality data was
collected from the Georgia Comprehensive Cancer Registry. Initial data collected from
the Georgia Cancer Trials database included the total number of cancer clinical protocols
and the total number of trial listings offered to adult cancer patients in the state. Data was
collected on all adult cancer trials to obtain a total number of cancer clinical trials in
Georgia. The first set of data regarding cancer trial information was collected in October
2006. A report was requested from the national TrialCheck database for all of adult
cancer clinical trials listed in the Georgia Cancer Trials database. Upon receipt of the
report, the information was entered into a Microsoft excel spreadsheet. Clinical trials
were characterized by the following: protocol identification number, Cancer Therapy
Evaluation Program identification number (CTEP ID), oncology practice name, cancer
type, trial type (i.e., treatment, prevention, supportive care, or other), and address.
Official protocol identification numbers were used to verify each protocol to ensure that
there were no duplicates. It is important to note the difference between what is described
as a protocol versus a cancer clinical trial listing in this study. Protocols refer to the
description of rules of how the study is to be carried out and the study purpose. Each
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study has a definitive protocol number that is unique to that specific trial. The number of
protocols is different from the number of cancer clinical trial listings because the listings
include the various locations in which protocols are offered. For example, if protocol A is
offered at 12 sites across the state then the protocol has 12 listings that should be included
when reviewing the number of trials.
Some oncology practices had numerous CTEP IDs, depending on how the trials
were initially entered by the research personnel at the practice. Therefore, oncology
practices with numerous CTEP IDs were grouped under one identification number to
avoid duplication. Addresses for the clinical trial locations were linked to oncology
practices and verified by Georgia Cancer Trials database, Georgia CORE portal, site
locations, and/ or the oncology practices’ official website. Addresses gathered in the
study reflect the physical street addresses for clinical trial locations, because P.O. boxes
cannot be geocoded. Suite numbers were also included in the point data.
In an effort to ensure accuracy, a report was sent to cancer clinical trials locations
in January 2007 to verify that their sites were accurately reflected in the database report.
Upon the dissemination of this report, the clinical trial information was updated for each
responding location. As a part of the update, studies from the Accelerated Community
Oncology Research Network (ACORN) were also added to the cancer clinical trial
listings. Before the update, approximately 50 percent of the ACORN studies were not
found in the Georgia Cancer Trials database. These trials were then added to Georgia
Cancer Trials, as a result of this study. It is important to note that the Georgia Cancer
includes approximately 95% of all cancer clinical trials in the state.
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A second data collection and verification process was conducted from March 8,
2007 to March 19, 2007. During this process, trials were updated from an additional
report requested from the national TrialCheck database. Trials from this data collection
period were added to the initial Microsoft excel spreadsheet that was compiled in
January. Duplicates and other internal listing problems involving oncology practices were
identified in this stage and can be found in the limitations section of the discussion
chapter.

The next step involved planning the analysis for the study. In order to view the
number of cancer clinical trials in Georgia, the information had to be changed to a format
acceptable by the ArcMap application in ArcGIS. After all corrections regarding
duplication of oncology practice were made, the excel spreadsheet was sent to the Office
of Health Information and Policy (under the Georgia DHR, Division of Public Health) to
be geocoded. The plan for analysis also consisted of collecting data in various formats to
create five sets of maps: 1) a general map of the number of cancer trials offered by
county, 2) a map of the number of trials by county and the incidence rates by major
cancer type, 3) a map of the ratios of cancer trials available to the number of new cancer
patients, 4) a map of the number of trials by county and the incidence rates of African
American patients by major cancer type, and 5) a map of the number of trials by county
and the mortality rates by major cancer type.

It is important to distinguish that there are two common models used to represent
geographic data: the vector data model and the raster data model. This study used the
vector data model. Objects in this study are represented by either a point or a polygon
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feature with well-defined boundaries, as a feature class. A feature class consists of a
collection of geographic entities with the same geometry type (such as point, line, or
polygon), the same attributes, and the same spatial reference. Feature classes can either
stand alone within a geodatabase or be contained within shapefiles, coverages, or other
feature datasets. Feature classes also allow homogeneous features to be grouped into a
single unit for data storage purposes. Feature boundaries are defined by x,y coordinate
pairs. X, Y coordinates are a pair of values that represents the distance from an origin
(0,0) along two axes, a horizontal axis (x) representing east-west, and a vertical axis (y)
representing north-south. On a map, x,y coordinates are used to represent features at the
location they are found on the earth's spherical surface. Points are generally defined by a
single x,y coordinate pair while polygons are defined by lines that close to form polygon
boundaries (Rushton 2006). The geocoded listing of Georgia cancer clinical trials
included these coordinates as point data.

Preparation of Additional Spreadsheets for Data Analysis

The next step was to prepare the geocoded data into spreadsheets that would later
be joined with the GIS county shapefile. Much of the preparation was done in the initial
spreadsheet. However, that data required further manipulation upon receipt in order to
tailor the information for the various types of maps. In order for the information to
translate into a readable file, the information needed to be saved as a delimited text file.
In addition, the data had to be joined with the existing shapefile or a new shapefile had to
be created. In this study, data was both joined to the Georgia shapefile map and
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additional shapefiles were created to view data. This required the creation of numerous
spreadsheets. A general spreadsheet listing the 159 counties in Georgia were compiled
with the heading “County Name” in order to match the one-to-one relationship needed to
join the same information with the county shapefile, which was also listed by county
name. Then, the number of trials in each county was paired with the corresponding
county name. An additional spreadsheet was created to list the number of trials in each
county by major cancer type: breast, colorectal, lung and prostate. Data retrieved for this
spreadsheet included: county name, number of trials, and major cancer type. The
spreadsheet was saved as a delimited text file to ensure readability in the ArcMap
application.

Next, two spreadsheets were combined. The first spreadsheet consisted of a listing
of cancer clinical trial locations across Georgia with the name of the institution, county,
and number of trials offered. Counties were labeled and identified for each cancer clinical
trial listing using the zip codes in the address of the institutions where clinical trials were
located. The county information was paired with the corresponding trial location and
verified using the U.S. Census website. Then, the second spreadsheet was created so that
the point data (all cancer clinical trial listings in the state) could be joined. In order to do
the second spreadsheet, the attribute table for the county shape file was referenced. Each
county was listed in the second spreadsheet in the same format used in the attribute table.

Additional spreadsheets were created utilizing cancer incidence and mortality
rates provided by the Georgia Comprehensive Cancer Registry. Each spreadsheet
contained information regarding county name and the corresponding incidence rates for

38
each of the major cancer types. This was also done for African American cancer
incidence by major cancer type as well as mortality rates for the entire Georgia
population. After these spreadsheets were created, the data was saved as a delimited text
file, in preparation for joining with the county shapefile data.

Conversion of point data into a shapefile
Because the information in this study was collected and geocoded as point data,
the information had to be converted into a shapefile of the trial locations in order to view
over patterns of incidence and mortality rates. A shapefile consists of vector data storage
in a format for storing the location, shape, and attributes of geographic features. A
shapefile is stored in a set of related files and contains one feature class. A single
shapefile generally contains at least three main files, and as many as eight.
An additional spreadsheet was required to layer the number of trials over maps
containing cancer incidence rates for each major cancer type. This was done using the
geocoded version of the master spreadsheet containing cancer clinical trial listings. The
data was filtered and sorted by major cancer type and the new spreadsheets were created
containing information needed to plot trials for each major cancer type. The master
cancer clinical trial spreadsheet contained a total listing of cancer clinical trials across the
state; therefore, the data needed to be sorted by major cancer type. Once the data was
sorted, the information was copied into a separate spreadsheet and labeled as the
geocoded version by major cancer type (i.e., Breast_Cancer_Clinical_Trials_Geocoded).
After further analysis, the file had to be reduced to one location in each county in order to
have one point representing the number of trials per county because there were numerous
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points in counties with multiple locations. Leaving this issue unaddressed would have
produced an inaccurate reflection regarding the density of trials. This data was used along
with the previously described spreadsheets in order to create maps that reflected cancer
incidence and mortality rates as a base map with the quantities of trials plotted over the
incidence rates. In an effort to increase accuracy, statistics regarding the frequency of
trials by county and major cancer type were analyzed in Statistical Package for the Social
Sciences (SPSS).

Constructing Maps

The analysis was executed by joining the information gathered in this study to the
ArcMap application in ArcGIS. A preliminary map showing the point locations was
performed through the following steps. First, the downloaded county shapefile was added
to the ArcMap application. Next, the delimited text file containing geocoded Georgia
cancer clinical trial listing was added as a layer to the Georgia county map file. The file
appeared as Georgia_Cancer_Clinical_Trial-Listing_4_2_07_Geocoded1.txt in the
application.

A join file was created to link the information gathered on the number of trials to
the ArcMap application. In order to create a join file, the information has to be listed in
the same sequence as the file in which it will be joined, as seen in figure 3.2. Once the
tables are joined, the quantities can be displayed.
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Figure 3.2 Joining Data in ArcView

Next, the ArcMap application was used to create a shape file for the number of
trials. The county information was linked to the shapefile by joining the two tables. Next,
the symbology screen was access through layer properties and the quantity field was
accessed through layer properties to view the quantity of trials by graduated color. The
value field selected was “number_of_trials”, in order to view the number of trials by
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county. Class breaks were selected with the colors graduating from yellow to orange, as
seen in figure 3.3.

Figure 3.3 Layer Properties Displaying Graduated Colors

Additional maps were done in 4 series. The first series was a basic map showing
county cancer clinical trial listings by major cancer type. This map was constructed
through the following steps. First the county shape file was added into ArcGIS. Next, the
data was joined to the spreadsheet join_file2. Then, the layer properties were changed by
creating quantity stratification and colors for the newly joined data. This was done in the
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quantities field. The cancer type was selected as the variable and the default setting was
selected for the number of natural breaks.
The next series of maps were created to show the cancer incidence as the base
data with the number of trials displayed as point data with density of cancer trial
locations shown by graduated symbol. This was done by conducting the following steps.
First the base map of the county shape file was joined to the delimited text major cancer
incidence file, previously described. Then, the layer properties were changed to reflect
the quantities of cancer incidence joined to the county shape file. The color range was
chosen and 5-6 natural breaks were selected (depending on the cancer type and pattern).
Next, the data file containing the limited geocoded cancer clinical trial information by
major cancer type was added. The X, Y data was displayed and the data was exported
into a shapefile. The data was then added as a separate layer on top of the base map with
incidence rate. The newly added data was then joined with the delimited text file
containing the number of trials by county and major cancer type. As previously noted,
this information only contained the county names listed with the number of trials in each
county by major cancer type. Next, the layer properties were changed to display the
quantities of trials by county. Graduated symbols were used to identify the quantity of
trials available. A separate map was constructed for each of the four major cancer types
using these steps.
The next series of maps were constructed to show the distribution of cancer trials
as it relates to patterns of cancer incidence rates among African American patients in the
state by major cancer type. This process was similar to the previously described map
construction. First, the county shapefile was added and joined with the cancer incidence
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rate join file. Then the geocoded limited file for the major cancer type was added. This
file was then converted into a new shapefile and layer. Next, the quantity distribution
colors were developed in the layer properties.
The final series of maps displayed the number of trials by mortality rates to reveal
if trials were available in counties with the highest rates of death. The mortality data
retrieved from the Georgia Comprehensive Cancer Registry was joined with the county
shapefile in ArcMap. The number of trials was mapped over the chlorepleth map using
graduated symbols. The next section will examine and present results found in the GIS
analysis of cancer clinical trial locations in Georgia.
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Chapter IV- Results
This study found that there are 321 cancer clinical trials (see Appendix A)
currently enrolling in Georgia. Protocols for the four major cancer types accounted for
42.1 percent of all protocols (see figure 4.1). This study also found that there are 961
listings of cancer clinical trials in Georgia. The listings of trials include the locations
where protocols are offered. This study also found that 53 percent of the cancer clinical
trials offered in Georgia were in the four major cancer types: 23% breast, 10% colorectal,
14% lung, and 6% prostate (see figure 4.2). This finding was interesting since the “big
four” cancers account for 58 percent of all cancer diagnosed and 53 percent of all cancer
deaths. This study found that cancer clinical trials in the four major cancer types did not
make up half of the cancer trials offered in the state.
Figure 4.1 Cancer Clinical Trial Protocols in Georgia by Major Cancer Type

Breast
17%
Colorectal
6%
Other
57%

Lung
13%
Prostate
7%
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Figure 4.2 Cancer Clinical Trial Listings in Georgia by Major Cancer Type

Breast
23%

Other
47%

Colorectal
10%
Lung
Prostate 14%
6%

Results from this study suggest that nearly 80 percent of the trials were treatment
trials, see table 4.1.

Table 4.1 Types of Cancer Clinical Trial in Georgia
Type of Trial

Number of
Trials

Treatment

767

Percent
79.8

Supportive care

46

4.8

Prevention

24

2.5

Other

124

12.9

Total

961

100.0

Of the 321 protocols found in this study, there were 961 total cancer clinical trials
offered in the state. It is important to point out that there is a total of 321 cancer trials
offered in Georgia at approximately 46 sites. The cancer clinical trial listing of 961
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reflects where the 321 cancer trials are offered. Therefore, the reference to cancer clinical
trial listings includes the actual locations where trials are being offered, not simply the
overall number of protocols. Table 4.2 shows the number of cancer clinical trial listings
by cancer type. Breast cancer trials are the leading type of cancer trial in Georgia, with
22.8 percent of the 961 listing of total trials; followed by lung (13.7 percent), colorectal
(13.1 percent), lymphoma (6.7 percent) and prostate (6.2 percent).
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Table 4.2 Number of Cancer Clinical Trial Listings by Cancer Type

Cancer Type

Frequency

Percent

Billiary Tract

1

.1

Bladder

3

.3

blood

5

.5

Blood

23

2.4

3

.3

Brain

Bone and soft tissue

20

2.1

Breast

219

22.8

Cervix

10

1.0

Colorectal

97

10.1

Esophageal

13

1.4

Gallbladder

8

.8

Gastrointestinal

23

2.4

Genitourinary

4

.4

Gynecologic

6

.6

Head and Neck

38

4.0

Kidney

18

1.9

Leukemia

57

5.9

Liver

3

.3

Lung

132

13.7

Lymphoma

64

6.7

Melanoma

35

3.6

Multiple Myeloma

9

.9

Myeloma

24

2.5

other

28

2.9

Other
Ovarian

2

.2

25

2.6

Pancreas

9

.9

Prostate

60

6.2

9

.9

Uterine

12

1.2

Vagina

1

.1

961

100.0

skin (non-melanoma)

Total

48

Cancer clinical trials were found in 15 counties across 24 cities. A complete
listing of cancer clinical trial listings by county can be found in table 4.3.

Table 4.3 Cancer Clinical Trial Listing by County

County
Bibb
Chatham

Number of
Cancer Trials

Percent

44

4.6

121

12.6

Clarke

17

1.8

Clayton

37

3.9

Cobb

96

10.0

227

23.6

24

2.5

7

.7

131

13.6

Gwinnett

42

4.4

Hall

47

4.9

DeKalb
Dougherty
Floyd
Fulton

Lowndes

26

2.7

Muscogee

33

3.4

Richmond

105

10.9

Spalding
Total

4

.4

961

100.0

In this study, trials were found at 46 sites across the state (see Appendix B). This
study also found that the majority of cancer clinical trials in Georgia were located in
metro-Atlanta counties. Table 4.3 shows that nearly 24 percent of all cancer trial listings
were found in DeKalb County. The number of trials varied outside of the metro-Atlanta
counties from 7 to 121 trials. There were also a greater number of trials in counties with
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medical schools. This study found that 55.8 percent of all cancer clinical trial listings
were located in metro Atlanta counties.

Table 4.4 Number of Cancer Clinical Trials by Major Cancer Type and County
County
Bibb
Chatham
Clarke
Clayton
Cobb
DeKalb
Dougherty
Floyd
Fulton
Gwinnett
Hall
Lowndes
Muscogee
Richmond
Spalding

Breast trials
11
21
6
9
28
32
5
1
33
10
15
5
10
31
2

Colorectal trials
2
16
2
2
10
24
3
0
12
5
2
3
5
6
1

Lung trials
6
17
4
4
17
25
2
3
18
9
5
5
3
13
0

Prostate trials
1
6
1
1
2
15
1
0
11
1
6
1
2
12
0

Findings from this study show that the majority of cancer clinical trials were
located in Fulton, Richmond, Cobb, Chatham and DeKalb counties. It is interesting that
the metro Atlanta counties and counties with University medical centers have the
majority of the trials in the state. Fulton, DeKalb, and Cobb counties are located in metro
Atlanta. Richmond and Chatham counties have University medical centers, Medical
College of Georgia and Mercer University School of Medicine, respectively. As seen in
table 4.4, these counties also tend to lead the state in the most trials in the major cancer
types.
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The following map contains a geographic representation of cancer clinical trials in the
state by listing.

Figure 4.3
Total Number of Cancer Clinical Trial Listings in Georgia by County
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Figure 4.3 exhibits the nature of cancer clinical trial distribution across the state.
Generally, color-coded distribution is only utilized to show rates or ratios; however, for
illustration purposes, this distribution is shown to give a basic view of trial quantity
distribution throughout the state. DeKalb County has the largest density of cancer clinical
trials, followed by Fulton, Chatham and Richmond counties. The following map shows
the distribution of breast cancer clinical trials in the state. The highest densities of trials
are offered in metro Atlanta counties.

Figure 4.4
Breast Cancer Trial Listings in Georgia, by County
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The following map, Figure 4.5, shows the distribution of colorectal cancer clinical
trials in the state. Most of the colorectal cancer trials offered in Georgia are also in metro
Atlanta. DeKalb County has the largest density of colorectal cancer trials of any county
in the state. This is partly due to the Winship Cancer Institute at Emory University.
Figure 4.5
Colorectal Cancer Clinical Trial Listings in Georgia, by County
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Figure 4.6
Lung Cancer Clinical Trial Listings in Georgia, by County

Figure 4.6 shows the basic distribution of lung cancer clinical trials in the state.
The largest number of trials appears mainly in metro Atlanta counties, with the exception
of Chatham County.
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Figure 4.7
Prostate Cancer Clinical Trials in Georgia by County

A basic distribution analysis of the prostate cancer clinical trials in the state shows
that the largest quantity of trials in DeKalb County, followed by Fulton and Richmond
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counties. The next series of maps will display cancer incidence rates by major cancer
types and the number of trials by county.

Figure 4.8
Breast Cancer Incidence Rates (1999-2003), Number of Breast Cancer Trials in
Georgia by County

-

The map above shows the distribution of breast cancer incidence rates in the state
as the base map. In addition, the numbers of breast cancer clinical trials are plotted over
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the incidence rates to view where the breast cancer trials are in relation to the rates of
new breast cancer cases. The darker pink color indicates a higher breast cancer incidence
rate while larger densities of trials are indicated by graduated circular symbols. This
study found that of the 11 counties with the highest rates of breast cancer incidence, only
one had cancer clinical trials available: Clarke county (see table 4.5)

Table 4.5. Presence of Cancer Trials in Georgia Counties with Highest Level Breast
Cancer Incidence
County

Schley
Ben Hill
Pickens
Calhoun
White
Lumpkin
Cherokee
Oconee
Clarke
Lanier
Rockdale

Breast Cancer
Incidence
Rate
202.0
158.3
156.1
151.5
148.3
147.5
144.3
143.2
142.6
141.1
140.7

Presence of
Breast Cancer
Clinical Trials
No
No
No
No
No
No
No
No
Yes
No
No
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Figure 4.9
Colorectal Cancer Incidence Rates (1999-2003), Number of Colorectal Cancer
Trials in Georgia by County

This study found that 13 counties in Georgia have colorectal cancer clinical trials
available. The largest quantity of trials is indicated by a larger circle in figure 4.9. This
figure reveals the number of colorectal trials available in each county layered over the
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colorectal cancer incidence rates. The findings suggest that the counties with the highest
incidence rates of colorectal cancer have no cancer trials available in those counties. A
large number of the colorectal trials are located in the metro Atlanta counties where the
colorectal cancer incidence rates are lower.
Table 4.6 Presence of Cancer Trials in Georgia Counties with Highest Level
Colorectal Cancer Incidence
County

Jasper
Terrell
Marion
Taylor
Hancock
Calhoun
Bacon
Lamar
Wilkes
Stewart

Colorectal
Cancer
Incidence
Rate
87.3
86.6
77.8
77.8
76.1
73.3
71.0
70.9
69.6
68.6

Presence of
Colorectal
Cancer
Clinical Trials
No
No
No
No
No
No
No
No
No
No

Calhoun and Lanier counties both have the highest incidence rates of breast and
colorectal cancer and neither have trials available. In addition, there are limited trials in
proximity to these counties.
Figure 4.10 shows the lung cancer incidence rates in Georgia with the number of
trials. Findings were similar to the disparities found in the figure 4.9. Counties with the
largest rates of new lung cancer cases have no lung cancer trials available.
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Figure 4.10 Lung Cancer Incidence Rates (1999-2003), Number of Lung Cancer
Trials in Georgia by County
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Table 4.7 Presence of Cancer Trials in Georgia Counties with Highest Level Lung
Cancer Incidence
County

Lung Cancer
Incidence
Rate

Lanier
Quitman
Ben Hill
Murray
Terrell
Clinch
Polk
Wilcox

129.0
122.9
122.7
116.1
113.2
111.7
109.6
107.3

Presence of
Lung Cancer
Clinical
Trials
No
No
No
No
No
No
No
No

Lanier County appears again as one of the counties with the highest levels of lung
cancer incidence and yet they have no cancer clinical trials available. Appendix C shows
the map with Georgia counties labeled.
An analysis of the number of prostate cancer clinical trials by incidence rates
revealed that 13 of the 159 counties in Georgia offer prostate cancer trials, as seen in
figure 4.11. Counties with the highest burden of prostate cancer had no prostate cancer
trials available. Consequently, trials available in neighboring counties were scant. This
study also found that the number of prostate cancer trials available across the state was
substantially lower compared to the number of breast, colorectal, and lung cancer trials.
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Figure 4.11
Prostate Cancer Incidence Rates (1999-2003), Number of Prostate Cancer Trials in
Georgia by County
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Table 4.8 Presence of Cancer Trials in Georgia Counties with Highest Level
Prostate Cancer Incidence
County

Prostate
Cancer
Incidence
Rate

Calhoun
Thomas
Terrell
Mitchell
Dooly

382.4
261.8
254.6
249.0
247.9

Presence of
Prostate
Cancer
Clinical
Trials
No
No
No
No
No

It is interesting to note that the highest rates of new prostate cancer cases are
largely comprised in South Georgia. Yet, these counties have no prostate cancer trials
available. Table 4.8 displays the five counties with the highest rates of prostate cancer
incidence. These findings indicate a serious public health issue, particularly since there is
only a combined five prostate cancer trials in the entire southwest corner of the state. This
also leads to a question regarding why there are no more than 15 trials found in one
county, compared to the number of trials available for breast, colorectal and lung cancers.
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Figure 4.12
Breast Cancer Incidence Rates in African Americans (1999-2003), Number of
Breast Cancer Trials in Georgia by County

Figure 4.12 shows the rates of new breast cancer cases in African American
women in the state. This analysis revealed that 2 of the 9 counties with the highest breast
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cancer incidence rates for African American women had breast cancer trials, Clarke and
Hall counties. The largest quantities of trials were found in Fulton, DeKalb, Cobb, and
Richmond.

Figure 4.13
Colorectal Cancer Incidence Rates in African Americans (1999-2003), Number of
Colorectal Cancer Trials in Georgia by County
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Figure 4.13 shows the colorectal cancer incidence in the African American
population by county and the number of trials available. Counties with the highest rates
of colorectal cancer incidence in African Americans, there were no trials present.
However, in counties with moderately high colorectal cancer incidence rates for this
population, trials were available in 5 out of 17 counties.
An analysis of lung cancer incidence rates in African Americans and lung trials
available to them found no trials available in the counties with the highest incidence
rates, as seen in figure 4.14. In addition, no more than six trials were available in counties
with the second highest level of lung cancer incidence in the African American
population. Furthermore, the highest quantities of trials were found in counties with
moderate lung cancer incidence rates. Two-thirds of the counties with the largest
quantities of trials were located in metro Atlanta.
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Figure 4.14
Lung Cancer Incidence Rates in African Americans (1999-2003), Number of Lung
Cancer Trials in Georgia by County
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Figure 4.15 displays the number of prostate cancer trials available by county and
prostate cancer incidence rates in the African American population. This study found that
there were no trials available in counties with the highest prostate cancer incidence rates.
In addition, the counties with the second highest levels of prostate cancer incidence rates
in this population had a single trial in 1 out of 26 counties.

Figure 4.15
Prostate Cancer Incidence Rates in African Americans (1999-2003), Number of
Prostate Cancer Trials in Georgia by County
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The next series of maps will display cancer mortality rates by major cancer type
and the number of trials by county.

Figure 4.16
Breast Cancer Mortality Rates (1999-2003), Number of Breast Cancer Trials by
County in Georgia by County

Figure 4.16 depicts the number of breast cancer trials by mortality rates of the
disease. There were no trials found in counties with the highest rates of breast cancer
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deaths. However, of the counties offering breast cancer trials, the largest number of trials
was found in counties with the second highest mortality rates.

Table 4.9 Presence of Cancer Trials in Georgia Counties with Highest Level Breast
Cancer Mortality Rates
County

Butts
Stephens
Pickens
Polk
McDuffie

Breast Cancer
Incidence Rate
44.4
43.2
39.5
36.1
35.2

Presence of
Breast Cancer
Clinical Trials
No
No
No
No
No

This study also analyzed the number of colorectal cancer trials by the rates of
colorectal cancer deaths, as seen in figure 4.17. Results show that there were no trials
available in counties with the highest mortality rates. In addition, there were no colorectal
cancer trials found in counties with the second highest rates of colorectal cancer deaths.
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Figure 4.17
Colorectal Cancer Mortality Rates (1999-2003), Number of Colorectal Cancer
Trials in Georgia by County
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Table 4.10 Presence of Cancer Trials in Georgia Counties with Highest Level
Colorectal Cancer Mortality Rates
County

Terrell
Screven
Ben Hill

Colorectal
Cancer
Mortality Rate
53.4
34.2
32.1

Presence of
Colorectal Cancer
Clinical Trials
No
No
No

Table 4.10 shows that there were no colorectal cancer clinical trials available in
counties with the highest rates of mortality for the disease. Terrell, Screven and Ben Hill
counties were the top three counties with the highest colorectal cancer mortality rates in
Georgia.
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Figure 4.18
Lung Cancer Mortality Rates (1999-2003), Number of Lung Cancer Trials in
Georgia by County

Figure 4.18 shows the number of lung cancer trials and mortality rates of lung
cancer by county. Results reveal that the counties with the highest rates of mortality have
no cancer clinical trials. Also, the counties with the second highest levels of lung cancer
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mortality have trials available in 0 out of the 35 counties with mortality rates between
84.1 and 109.2 per 100,000, as seen in table 4.11.
Table 4.11 Presence of Cancer Trials in Georgia Counties with Highest Level Lung
Cancer Mortality Rates

County

Murray
Ben Hill
Terrell
Clinch
Bleckley
Walker
Lanier

Lung Cancer
Mortality Rate
109.2
108.8
102.1
97.4
96.3
88.6
88.2

Presence of
Lung Cancer
Clinical Trials
No
No
No
No
No
No
No

The next map displays the number of prostate cancer clinical trials in the state by
prostate cancer mortality rates, see figure 4.19. There were no trials found in counties
with the highest death rates from prostate cancer. However, a substantial number of trials
were found in counties with the second largest prostate cancer mortality rates.

.
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Figure 4.19
Prostate Cancer Mortality Rates (1999-2003), Number of Prostate Cancer Trials in
Georgia by County
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Table 4.12 Presence of Cancer Trials in Georgia Counties with Highest Level
Prostate Cancer Mortality Rates
County
Burke
Peach
Harris
Brooks
Mitchell
Elbert
Sumpter
Coffee

Prostate Cancer
Incidence Rate
73.9
66.2
63.1
60.2
58.8
52.5
51.6
51.4

Presence of Prostate
Cancer Clinical Trials
No
No
No
No
No
No
No
No

There were also no cancer clinical trials found in counties with the highest
prostate cancer mortality rates. This finding is interesting, particularly since the death
rates for prostate cancer are higher than those of breast and colorectal cancers. Also,
many of the counties with the highest prostate cancer mortality rates are in Southeast
Georgia were there are no more than 5 trials in the entire region.
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Chapter V- Discussion
Cancer is a serious public health problem across the state of Georgia. In an effort to
identify potential health disparities regarding cancer clinical trials, an analysis of trials by
location, cancer type, cancer incidence rates, cancer mortality rates and racial patterns in
Georgia counties was conducted. To the best of our knowledge, this paper represents the
first study to examine the number of cancer clinical trial listings across the state of
Georgia by major cancer type, incidence rates, mortality rates, and geographic
distribution of racial patterns. Recent studies suggest that location of and distance to
treatment centers affect a patient’s decision on whether or not to enroll in a clinical trial
(Celaya et al. 2006). This is important because cancer clinical trial participation is low
and barriers to cancer clinical trials access should be minimal (Comis 2003). This study
did not focus on childhood cancer clinical trials because there is a 60 percent accession
rate of cancer clinical trials in pediatric patients. This is substantially higher than the
estimated 3 percent of adult cancer patients who participate in clinical trials (NCI 2001).
In this study, the entire dataset was not found in a central location. Information was
gathered from various sources, including the Georgia Division of Public Health Office of
Health and Information Policy, the Georgia Comprehensive Cancer Registry, the Georgia
Cancer Trials Database, and community oncology practices. These sources provide valid
data regarding cancer trial locations in Georgia, geographic display of Georgia counties
and cancer incidence and mortality rates in the state, respectively. The analysis was
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sconducted using GIS software. GIS provides the means for identifying and displaying
geographic patterns, thus providing a useful investigation tool for cancer screening,
mortality and incidence rates. In addition, GIS can be used to examine geospatiallyrelated questions regarding availability of cancer clinical trials in Georgia.
This study found that the largest number of cancer clinical trials in Georgia were
concentrated primarily in metro Atlanta counties. While this data was not directly
comparable to previous published studies, findings from this study can be used as
introductory information to further understand cancer clinical trial availability in Georgia.
Findings from this study also suggest that there are disparities in cancer clinical trial
access as defined by locations across the state. Tables 4.5-4.12 show that counties with
the highest rates of incidence and mortality for breast, colorectal, lung and prostate
cancers have little or no cancer clinical trials available.
Results from this study are demonstrative of the problems facing cancer clinical trial
availability (directly) and cancer clinical trial enrollment (indirectly) in Georgia. This
issue is not unique to Georgia. The nation as a whole suffers from few availability of
cancer clinical trials for disparate populations (Comis, 2003). Lack of sufficient
availability of trials has proven to be a barrier to enrollment. This is an important issue
because cancer clinical trials are crucial in the evaluation of safe and effective new drug
treatments. Since clinical trials rely on volunteers, it is critical to make trials available
and accessible to cancer patients. This may reduce disparities regarding treatment options
and give cancer patients treatment alternatives to a disease perceived often times as a
death sentence.
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This study also found that 42.1 percent of the cancer clinical protocols offered in
Georgia were in the four major cancer types (23% breast, 10% colorectal, 14% lung, and
6% prostate, see Figure 4.2). This finding raises questions regarding whether 42.1 percent
of all cancer clinical protocols being in the major four cancers is sufficient, particularly
since the major cancer types account for 58 percent of all cancer diagnoses and 53
percent of all cancer deaths (Singh 2005), . This is an important issue because breast,
colorectal, lung, and prostate cancer protocols did not make up half of the cancer trials
offered in the state; however, they account for more than half of cancer diagnoses and
deaths.
This study also found that the majority of breast and lung cancer ongoing trials were
in metro Atlanta counties compared to rural counties. As of March 2007, there were only
15 counties in the state offering cancer clinical trials. This study also found that 55.8
percent of the trial listings were located in metro Atlanta counties. This study also found
that no trials were offered in counties with the highest colorectal, lung and prostate
cancer incidence rates. In addition, less than six trials were found in counties with the
highest incidence rates of breast cancer. This is important when answering the question of
whether cancer clinical trials are adequately available in the state. Findings in this study
show that the highest distribution of cancer trials by major cancer type appears mostly in
metro Atlanta counties.
When investigating the major cancer types by incidence rates and number of trials, it
is important to study racial disparities. Due to limitations with incidence and mortality
data available from the Georgia Comprehensive Cancer Registry, the African American
population was the only racially diverse group analyzed in this study. This study found
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that no colorectal, lung, and prostate trials were available for African Americans in
counties with the highest incidence rates. In addition, 2 of the 9 counties with the highest
breast cancer incidence rates for African American women had trials available.
Therefore, this study shows that there is a disparity among the African American
population in Georgia, regarding the number of trials available to new cancer patients.
This also implies that strategic planning is needed to address the cancer clinical trial
availability for minority patients in the state.
This study also found that there were no cancer clinical trials available for counties
with the highest mortality rates for breast, colorectal, lung and prostate cancers. This
finding indicates that there are no trials available in counties where patients are dying the
most. This is disheartening, particularly for counties with the highest breast and prostate
cancer mortality rates because there were no trials available within 50 mile proximity.
Generally, disparities in medical care exist in the following populations: minorities,
rural residents, and the elderly. Since the enactment of the National Institutes of Health’s
Revitalization Act of 1993, many cancer researchers have place an increased focus on
recruiting underrepresented populations in clinical trials (McCray 2000). As Georgia
invests the state-allotted tobacco settlement money in cancer research, it is important to
leverage these funds to decrease the level of the asymmetry of information regarding
cancer clinical trial locations and availability. Findings from this study suggest that there
are not an adequate number of cancer clinical trials available in counties experiencing the
highest burden of the disease.
Strengths of this study include that the data was obtained from Georgia’s only statespecific cancer clinical trial database. This is particularly important since there are
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various cancer clinical trial registries with different reporting techniques. Having a statewide cancer clinical trial database helps with the accuracy of the cancer clinical trial
listings. The Georgia Cancer Trials database is vital because it details the exact locations
where cancer trials are offered, which is not the case with the national cancer clinical trial
database. Oftentimes, clinicaltrials.gov will list the state and cities only, with no
indication of the actual location of the trial.
An additional strength of this study is the use of GIS to map cancer clinical trial
locations. This is particularly helpful since cancer incidence and mortality reporting is
done using this software. GIS allows more precise plotting of cancer trial locations
compared to other mapping software. In addition, exact addresses where used in this
study to increase accuracy of the point data. Also, the information retrieved for the
Georgia Cancer Trials database was verified with oncology practices across the state to
ensure accuracy.
It is important to discuss limitations involved in the study. First, there were
duplicates found with the Georgia Cancer Trials database. As stated previously, cancer
clinical trials are required to be registered. Consequently, there is no centralized
registration database to ensure non-duplicative listings of oncology practices. There were
numerous inconsistencies found with the way trials were listed by oncology practice/
institution. For example, The Medical Center- John B. Amos Cancer Center was listed as
both “The Medical Center” and as “John B. Amos Cancer Center”. At first glance, it was
not apparent that this was the same institution. However, after sending the report to the
site and discussing with their clinical research staff, it was found that this was the same
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site and research staff entering the data into the national database was using different
forms of the organization’s name.
This type of error was also found at Eisenhower Medical Center, Nancy N. and J. C.
Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Northside Hospital Cancer
Center, Medical College of Georgia Cancer Center, and Charles B. Eberhart Cancer
Center at DeKalb Medical Center. Each location appeared at least twice in the database
under variations of their true name. These inconsistencies were noted and corrected in the
Georgia Cancer Trials database as well as the dataset for this study.
The existence of multiple practices and reporting were also limited this study. Many
oncology practices have satellite clinics that are not currently being captured in the
national database. For example, Wellstar Health System has numerous satellite facilities.
All of these facilities may not be listed in the national or Georgia Cancer Trials database.
This is an issue of user error where the individual entering information at the oncology
practices does not give all satellite locations and the time of data entry. However, this
issue does not account for a significant change in the trial listing. Many of the satellite
locations are in the same counties as the parent institution.
This study was also limited by the availability of cancer morbidity and mortality data
available from the Georgia Comprehensive Cancer Registry. The mortality rate for
African Americans by county was not included in this study due to the lack of data from
a significant number of counties. Much of the data regarding African American cancer
mortality rate by county was suppressed. Therefore, the data was not useful to compare
cancer clinical trial availability as it relates mortality rates of African American patients
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because mortality rates were not able to be captured (value was less than five) in most of
the counties.
Another limitation of the study deals with capturing the cancer clinical trial listings
by counties. This may limit the study because patients are not confined to participating
solely in cancer clinical trials offered in their counties of residence. In many cases,
patients must travel outside of their residing county, and maybe outside of their state, in
order to enroll in a cancer clinical trial. For example, patients outside of DeKalb County
may be participating in cancer clinical trials at the Emory Winship Cancer Institute. This
study may be limited in scope because it assesses whether trials are located in counties
with the highest disease burden and does not account for patient travel from other
counties, mainly because data regarding patient accrual and travel distance was not
available for this study.
The lack of data regarding the number of patients enrolled in cancer clinical trials
gives rise to another limitation of this study. This information would provide further
indication of where most patients enroll and how far the travel to participate in a cancer
clinical trial. There have been discussions from the Georgia Center for Oncology
Research and Education regarding the feasibility of collecting patient accrual data.
Collection of this data is important to achieve the objective 6.1 of the Institute of
Medicine Report on Assessing the Quality of Cancer Care in Georgia (Eden and Simone
2005).
Because travel distance to the clinical trial location is a major factor in participation,
particularly in minority communities, it is important to have some baseline information
regarding cancer clinical trial availability at the county level. Joining the number of trials
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by county with the cancer incidence and mortality rates may limit the scope of this paper.
More data should be collected regarding how far cancer patients travel to participate in
cancer clinical trials in Georgia to better understand whether an appropriate number of
cancer clinical trials are being offered in the state at the local level.
It is important to capture information regarding how many cancer clinical trials is
considered sufficient, particularly in rural counties. This study found that counties outside
of the metro area had substantially less trials than metro Atlanta counties. This is
important because protocol availability is limited to participating sites. This is
particularly important because there is a large area in the southeast portion of the state
that has no cancer clinical trials offered. This study found that Chatham County was the
closest county in that region with a large density of trials. It was also the county with the
largest density of trials outside of metro Atlanta counties. However, this raises the
question of whether or not patients in this area would be willing to drive to Chatham
County to participate in a cancer clinical trial.
It is the recommendation of this paper that Georgia invest resources to collect data
regarding how many cancer patients participate in cancer clinical trials and where cancer
clinical trial participation is the highest. This would not only help to assess the quality of
clinical cancer care in the state, but it will also give the medical community pertinent
information about whether there are enough trials available for those who wish to
participate. This information would also indicate the type of trials that accrue patients and
which oncology practices conduct the most clinical research. This data can be compared
with cancer morbidity and mortality data to see if the cancer clinical trials that accrue the
most patients, actually reflect the burden of cancer in the state. Furthermore, it would
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answer whether patients are being accrued to studies that are in the “Big Four” cancer
types: breast, colorectal, lung, and prostate cancers.
It is hopeful that findings from this study will assist with determining disparities in
cancer clinical trial availability and state cancer planning. This study should spark
interest in and resources towards securing a strategic approach to the offering of cancer
clinical research in Georgia. It should also trigger discussion regarding the following
three questions:
1. What do we want the cancer clinical trial picture to look like in 2, 5, 10
years?
2. What is an adequate number of cancer clinical trials, by a specific parameter?
3. How will we secure strategic placement of cancer clinical trials across
Georgia?

With an estimated 36,000 Georgians diagnosed with cancer annually (Singh et al.
2005), this analysis should help define baseline data and help guide future cancer
research planning. The purpose of this study was to determine the density of cancer
clinical trial locations within the state. This study found that being a resident of metroAtlanta or living in a county with a medical schools present increased the probability of
cancer clinical trial availability. However, more trials were found to be available per
cancer patient outside of metro Atlanta counties.
The social implications of this study are important in ensuring the availability of and
access to cancer clinical trials across the state. This is particularly critical in minority
populations who are generally more susceptible to cancer. African American men and
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women have an increased likelihood of developing cancer in their lifetime (Singh et al
2005). This study found that, in Georgia, disparities exist in both cancer morbidity and
cancer clinical trial availability. Density of cancer clinical trials is higher in metroAtlanta. Therefore, areas located outside of metro-Atlanta have unequal distribution of
cancer trials. The cancer burden is higher in minorities and rural patients. In addition,
counties with medical schools had an increased chance of having a substantial number of
cancer clinical trials compared with other non metro counties.
It is important to note that there is an Atlanta Community Clinical Oncology
Program (Atlanta CCOP) that was initiated in 1993 by NCI to provide more access to
cancer clinical trials among community oncology practices in the Atlanta area. Saint
Joseph’s Healthcare of Atlanta is the parent institution for the Atlanta Regional CCOP
(http://www.atlantaccop.org/). There are eight institutions involved with Atlanta Regional
CCOP: Saint Joseph’s Hospital of Atlanta, Charles B. Eberhart Cancer Center at DeKalb
Medical Center, Northside Hospital, Piedmont Hospital, Wellstar Cobb Hospital,
Kennestone Cancer Center at Wellstar Kennestone Hospital, Southern Regional Medical
Center, and Gwinnett Health System. CCOP protocols are offered at all of the CCOP
locations. This increases the availability of cancer clinical trials in the previously listed
Atlanta oncology practices. These protocols may be present in community practices
across the state, but because those practices are not a part of the Atlanta Regional CCOP,
it is not guaranteed that the CCOP trials will be available.
In an effort to make more trials available across the state, it is the recommendation of
this paper that non-Metro Atlanta oncology practices be allowed to participate in Atlanta
Regional CCOP trials. This would ensure that smaller practices that wish to increase their
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offerings of cancer clinical trials would easily be able to do so. In addition, this would
instantly increase the cancer clinical trial listings across Georgia. This type of schema is
similar to businesses that franchise their organizations in an effort to reach a wider
audience to increase profits. Increasing access to Atlanta Regional CCOP trials in nonMetro Atlanta areas would help to make trials available to a larger number of cancer
patients in an effort to decrease disparities and adverse outcomes. This may require a
statewide collaboration using members of the Georgia CORE network and partnerships
with the Atlanta Regional CCOP.
Furthermore, this study recommends that Georgia focuses on a strategic approach to
the placement or dispersal of cancer clinical trials. It is important for patients to have a
variety of options regarding cancer clinical trials. This may require investing resources in
pilot programs for clinical research in counties which showed minimal cancer trial
availability, particularly in Floyd, Lowndes and Muscogee counties.
There are an estimated 5,000 trials offered in the United States (NCI 2001). Though
this study found that Georgia has 321 protocols, totaling 961 listings, a large portion of
the total trials were located in metro-Atlanta counties. Therefore, researchers, public
health officials, and cancer advocates should secure equitable access of cancer trials
across the state. Findings of the study showed that there are disparities in the availability
of cancer clinical trials across the state, particularly in rural and non Metro-Atlanta areas.
This is particularly important since this study found that counties with the greatest
disease burden had no trials available. Therefore, a concerted effort should be made to
ensure that trials are available in or near counties with the highest cancer incidence and
mortality rates.
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It is also the recommendation of this study that oncologists and public health officials
in the state adopt a plan to address clinical trial disparities, specifically targeting counties
outside of the metro-Atlanta area. First, officials should ensure an adequate number of
trials be available across the state by increasing the number of trials available at existing
sites. This may require a fund source for increased staffing capacity.
Results from this study showed that the cancer clinical trial listings across counties
varied from 4 to 227. The baseline data found in this study should provide the oncology
community and public health officials with information about the state of cancer clinical
trials in the state and where the researchers want the state to be in the next 5,10, and 15
years. This is particularly important in counties that lack the presence in the metro area as
well as counties that lack medical schools. This is a huge issue because it implies that
there is disproportionate access to cancer trials.
In conclusion, this study set out to answer three important questions regarding cancer
clinical research in Georgia: 1) what is the geographic distribution of cancer clinical trials
in Georgia, 2) are cancer clinical trials available in counties with the highest burden of
disease, and 3) is there a disparity in cancer clinical trial locations as it relates to racial
pattern? Findings from this study showed that in March 2007, there were 321 protocols
for cancer clinical trials offered at 46 sites across the state. This study also suggests that
there were no trials available in counties with the highest cancer incidence and mortality
rates for colorectal, lung and prostate cancers. Thirdly, there were similar findings when
viewing the number of trials available for African American cancer patients, by incidence
rate.
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This study addresses the issue of information asymmetry by providing the number of
cancer clinical trial locations in Georgia and identifying disparities associated with cancer
trial locations and where the disease burden is greatest. This study also shows the
importance of having baseline information to display the state of cancer clinical research.
As the second leading cause of mortality in the state, billions of dollars have been
invested in cancer clinical research. It is important to invest resources in reducing this
disproportionate gradient of information and cancer disparities across the state.
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Appendix A
Georgia Cancer Clinical Trial Protocols
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.

#123
0230B
0405-2006
0414-2006
0466-1998
0533-2003
0596-2004
0693-2002
1 R01 MH071580-01A2
10105
1048-2001
11800
11961
1341-2004
1342-2004
136
150106
174-2004
198-2002
20040213
2005_010
26866138CAN2007
3160A4-200
3410
553
60104
70103
9665
9760
Å6-003
A8501001
ACORN AEJSINS0601
ACORN ALJBMM0502
ACORN ALSSNBC0401
ACORN ALSSOPR0501
ACORN B9E-US-S377
ACORN H3E-MC-JMEN
ACORN H6Q-MC-JCBJ(b)
ACORN INS0601
ACOSOG-Z1031
ACOSOG-Z6041
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42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.

ACOSOG-Z9001
ACRIN-6673
AMC-038
AMD3100-2112
American BioSciences-CA023
Amgen-20060136
AMGEN A147
AMGEN A244
ANTISOMA-AS1404-203
AOI-206
AOI-208
AOI-211
AOI-215
APP-C2006-01
AVF3430n
AVF3671g
AVF3693g
AVF3694g
AVF3991n
Bayer-11961
BIOCRYST-BCX1777-T-04-201
BIOVEST-BV301
BMS-CA183001
BMTCTN-0102
BMTCTN-0201
BRE 0303
CA183-002
CA225251
CALGB-100104
CALGB-10105
CALGB-20203
CALGB-30406
CALGB-30407
CALGB-40101
CALGB-49907
CALGB-50203
CALGB-50303
CALGB-70301
CALGB-80101
CALGB-90202
CALGB-90401
CALGB-9665
CALGB-C80405
CAMN107A2109
CAN-NCIC-LY.12
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87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.

CAN-NCIC-MA.27B
CAN-NCIC-MA27
CAN-NCIC-MAP3
CAN-NCIC-MY10
CB01-202
CCBX001-049
CCCGHS-NCI-T98-0085
CCCWFU-71103
CCCWFU-98301
CDC-NCCDPHP-R-01-PH-000018
CG53135-CLN-12
CICL670AUS03
CLTR0105-201
CMM-95079
CONCEPT L-9444
CP02-0452
CP02-0555
CR008566
CSU-GCC-161
CTKI258A2103
CTSU E2805
CYC202-06-14 (A1)
CZOL446 EUS24
CZOL446E2352
CZOL446GUS63
D9902B
DFCI-04006
DOCET_L_00712
DUMC03
E1Y03
ECOG-1697
ECOG-1900
ECOG-1C99
ECOG-1Y97
ECOG-2602
ECOG-5501
ECOG-5597
ECOG-5998
ECOG-E1302
ECOG-E1B03
ECOG-E1F03
ECOG-E2204
ECOG-E2501
ECOG-E2603
ECOG-E2805
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132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.

ECOG-E2902
ECOG-E2Z04
ECOG-E3204
ECOG-E3803
ECOG-E3903
ECOG-E4203
ECOG-E4402
ECOG-E4903
ECOG-E5202
ECOG-E5204
ECOG-E6202
ECOG-E6501
ECOG-PACCT-1
ECOG-S9346
ECOG PACCT-1
Eli Lilly B9E-US-S182
Eli Lilly B9E-US-S377
Eli Lilly H6Q-MC-JCBJ
ENRICH Study
EU312-97
EU822-03
FCCC-FCRB-04-003-P
FHCRC-1938.00
FHCRC-1992.00
FHCRC-2054.00
G-0029
G-0034
GOG-0130E
GOG-0136
GOG-0146O
GOG-0146Q
GOG-0187
GOG-0188
GOG-0192
GOG-0198
GOG-0199
GOG-0204
GOG-0206
GOG-0209
GOG-0210
GOG-0211
GOG-0212
GOG-0218
GOG-0219
GOG-0222
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177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.

GOG-0227c
GOG-0232B
GOG-173
GOG-174
GOG-175
GSK-EGF103659
GSK-EGF30008
GV-001.004
H57/CCH420680-05
HN 0501
Hx-CD4-110
IBCSG-24-02
IBCSG-25-02
IBCSG-27-02
IRB3 021-2005
JHOC-J0252
JNJ-26866138-LYM-3001
KOS-202/NO18401
LCCC 0512
M05-780
MCC-0203
MCC-0502
MCSP-00-0107
MDA-ID-00156
MDX010-20
MGH-000084
MILLEN.EVERECT
NABTT-0306
NABTT-0307
NABTT-0401
NABTT-0404
NABTT-0501
NABTT-0503
NABTT-0504
NABTT-2201
NABTT-9806
NABTT-9902
NABTT-9910
NCCTG-N0147
NCCTG-N0177
NCCTG-N01C5
NCCTG-N02C4
NCCTG-N0434
NCCTG-N0437
NCCTG-N04C7
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222.
223.
224.
225.
226.
227.
228.
229.
230.
231.
232.
233.
234.
235.
236.
237.
238.
239.
240.
241.
242.
243.
244.
245.
246.
247.
248.
249.
250.
251.
252.
253.
254.
255.
256.
257.
258.
259.
260.
261.
262.
263.
264.
265.
266.

NCCTG-N9943
NCI-04-C-0001
NCI-06-C-0043
NCI-7306
NCI-92-C-0137M
Novacea 011-007
Novacea 011-015
NSABP-B-36
NSABP-B-37
NSABP-B-38
NSABP-B-39
NSABP-B-40
NSABP-B-42
NSABP-C-09
NSABP-C-10
NSABP-R-04
NTI-0303
NTI 0501
ONCOTHER-20052183
ONCOTHER-MAC001
OSI-774-203
OSI-774-302
OSI3364g
PC B305/02
PC B305/04
Perifosine 212
Perifosine 217
POI-02818
RTOG-0123
RTOG-0212
RTOG-0214
RTOG-0232
RTOG-0233
RTOG-0247
RTOG-0320
RTOG-0421
RTOG-0424
RTOG-0521
RTOG-0522
RTOG-0525
RTOG-L-0117
SEGO_DOXIL_CONS2005
STAN-973
STR 0303
SWOG-8947
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267.
268.
269.
270.
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
288.
289.
290.
291.
292.
293.
294.
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.
309.
310.
311.

SWOG-9007
SWOG-S0008
SWOG-S0016
SWOG-S0028
SWOG-S0106
SWOG-S0124
SWOG-S0220
SWOG-S0221
SWOG-S0226
SWOG-S0230
SWOG-S0232
SWOG-S0306
SWOG-S0307
SWOG-S0309
SWOG-S0329
SWOG-S0331
SWOG-S0334
SWOG-S0350
SWOG-S0414
SWOG-S0415
SWOG-S0424
SWOG-S0425
SWOG-S0429
SWOG-S0430
SWOG-S0434
SWOG-S0435
SWOG-S0508
SWOG-S0509
SWOG-S0511
SWOG-S0515
SWOG-S0536
SWOG-S9704
SWOG-S9910
SWOG-S9921
SWOG-S9925
SWOG BMT CTN 0102
TG-001
TM-601-002
TRIAD BOI/Muscositis
U2963n
UCLA-0307121-01
UCSD-040749
UMN-2004UC035
VBLT980-04
VSLI-06-ALL
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312.
313.
314.
315.
316.
317.
318.
319.
320.
321.

VU-VICC-HN-0501
WCI-1078-05
WCI-752-02
WCI1950-04
WCI901-04
WCI957-04
WILEX-WX-2003-07-HR
XCYTE-XT004
XL119-001
XT009
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Appendix B
Cancer Clinical Trial Listing by Institution
Institutions

Number
of trials

Percent

Atlanta Cancer Care - Roswell

8

.8

Atlanta Cancer Care at St. Joseph

1

.1

Augusta Oncology Associates - Walton
Way

49

5.1

Blood and Marrow Transplant Group of
Georgia

4

.4

Central Georgia Cancer Care, PC - Macon

12

1.2

Charles B. Eberhart Cancer Center at
DeKalb Medical Center

43

4.5

Clayton State University

1

.1

Cobb Memorial Hospital

1

.1

Columbus Clinic, PC

2

.2

82

8.5

7

.7

10

1.0

Georgia Cancer Center for Excellence at
Grady Memorial Hospital

8

.8

Georgia Cancer Specialists - Northside
Office

1

.1

Georgia Cancer Specialists - Tucker

5

.5

Georgia Urology - Atlanta

3

.3

Gwinnett Medical Center

Curtis & Elizabeth Anderson Cancer
Institute at Memorial Health University
Medical Center
Eisenhower Army Medical Center
Emory Crawford Long Hospital

34

3.5

Harbin Clinic

7

.7

Kennesaw State University

1

.1

Kennestone Cancer Center at Wellstar
Kennestone Hospital

38

4.0

Medical Center of Central Georgia

32

3.3
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Medical College of Georgia Cancer Center

43

4.5

Medical Oncology Associates, PC

2

.2

Morehouse School of Medicine

1

.1

Mount Vernon Clinical Research, LLC

1

.1

Nancy N. and J. C. Lewis Cancer and
Research Pavilion at St. Joseph's/Candler

37

3.9

Northeast Georgia Cancer Care, LLC

17

1.8

Northeast Georgia Medical Center

47

4.9

Northside Hospital Cancer Center

39

4.1

Northwest Georgia Oncology Centers, PC Marietta Center

17

1.8

Peachtree Hematology and Oncology
Consultants, P.C.

11

1.1

Pearlman Comprehensive Cancer Center
at South Georgia Medical Center

26

2.7

Phoebe Cancer Center at Phoebe Putney
Memorial Hospital

24

2.5

Piedmont Hospital

40

4.2

Saint Joseph's Hospital of Atlanta

37

3.9

South Fulton Medical Center

4

.4

Southeastern Gynecologic Oncology, LLP Northside

2

.2

36

3.7

Spalding Oncology Services

4

.4

Suburban Hematology-Oncology
Associates, PC

8

.8

Summit Cancer Care

2

.2

31

3.2

Southern Regional Medical Center

The Medical Center Inc., John B. Amos
Community Cancer Center
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Veterans Affairs Medical Center - Atlanta
(Decatur)

21

2.2

Veterans Affairs Medical Center - Augusta

4

.4

35

3.6

WellStar Cobb Hospital

4

.4

Winship Cancer Institute of Emory
University

Windy Hill Hospital

119

12.4

Total

961

100.0
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Appendix C
Georgia Counties

